Metastatic Pancreatic Adenocarcinoma (mPDAC) – Market Access and Reimbursement Insights Report – 2025

Metastatic Pancreatic Adenocarcinoma (mPDAC) Market Access and Reimbursement Insights

Thelansis’s “Metastatic Pancreatic Adenocarcinoma (mPDAC) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.

Metastatic Pancreatic Adenocarcinoma (mPDAC) Overview

Pancreatic Cancer (PC) is a lethal malignancy, with its prevalence, although relatively low, steadily increasing each year. Metastatic PC, categorized as late-stage (stage IV), represents the most advanced form of the disease, boasting an even higher fatality rate compared to other stages. Notably, patients affected by PC typically lack specific clinical manifestations. The major signaling pathways in metastatic pancreatic cancer include Epithelial-Mesenchymal Transition (EMT) and NF-κB (nuclear factor-κ-light-chain-enhancer activated B cells). Upon diagnosis, it is frequently observed that PC has already metastasized to a significant extent, rendering curative surgery unfeasible. However, imaging techniques such as CT, utilizing X-rays to generate cross-sectional images of the body, play a pivotal role in accurately assessing metastatic spread and offering crucial insights into treatment strategies, especially for tumors on the borderline of resectability. With the advanced stage and widespread dissemination characteristic of metastatic PC, surgical removal as a treatment modality is often not feasible.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.

*Survey and interview discussion guide are customized based on client requirements

Deliverables format:

• PowerPoint presentation

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Key business questions answered:

• Market access and reimbursement for current therapies
• Coverage on plans
• Market access restrictions
• Rebates and contracting
• Factors influencing formulary access
• HEOR requirements and influence, etc.
• Expected market access and reimbursement for key emerging therapies
• Level of awareness
• Anticipated coverage on plans
• Factors that would improve market access
• Pricing, etc.
• Impact on brand use
• Key factors driving and limiting brand use
• Best and worst performers on market access, etc.
• Evolving environment
• Payer expectations from emerging therapies
• New policies and their expected impact, etc.
• Advise to drug manufacturers and developers

Read more: Metastatic Pancreatic Adenocarcinoma (mPDAC) – Market Access and Reimbursement Insights Report – 2025